AKBA vs GILD: Which Stock is Better?
Side-by-side comparison of Akebia Therapeutics Inc and Gilead Sciences Inc in 2026
AKBA
Akebia Therapeutics Inc
$1.55
GILD
Gilead Sciences Inc
$139.77
Key Metrics Comparison
| Metric | AKBA | GILD | Winner |
|---|---|---|---|
| Market Cap | $417.89M | $174.33B | GILD |
| P/E Ratio | N/A | 20.72 | GILD |
| EPS (TTM) | $N/A | $6.78 | GILD |
| Revenue Growth | 0.2% | 0.0% | AKBA |
| Gross Margin | 82.9% | 78.8% | AKBA |
Analyze AKBA
Full quant analysis
Analyze GILD
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is AKBA or GILD a better investment?
Comparing AKBA and GILD: Akebia Therapeutics Inc has a market cap of $417.89M while Gilead Sciences Inc has $174.33B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between AKBA and GILD?
AKBA (Akebia Therapeutics Inc) and GILD (Gilead Sciences Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: AKBA or GILD?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: AKBA or GILD?
AKBA has higher revenue growth at 0.2% vs 0.0% for GILD.
Which company is more profitable: AKBA or GILD?
Akebia Therapeutics Inc (AKBA) has higher gross margins at 82.9% compared to 78.8% for GILD.
Which is the larger company: AKBA or GILD?
Gilead Sciences Inc (GILD) is larger with a market cap of $174.33B compared to $417.89M for AKBA.
Should I buy AKBA or GILD in 2026?
Both AKBA and GILD have investment merit. AKBA trades at $1.55 while GILD trades at $139.77. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between AKBA and GILD stock?
Key differences: Market Cap ($417.89M vs $174.33B), P/E Ratio (N/A vs 20.7x), Revenue Growth (0.2% vs 0.0%), Gross Margin (82.9% vs 78.8%).